Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Average Price Target of $4.75

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have earned a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $4.75.

IPSC has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Tuesday, September 29th. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of IPSC. Versant Venture Management LLC acquired a new position in shares of Century Therapeutics during the 1st quarter worth $27,495,000. BlackRock Inc. acquired a new stake in shares of Century Therapeutics in the second quarter valued at about $19,825,000. Commodore Capital LP acquired a new stake in shares of Century Therapeutics in the first quarter valued at about $19,652,000. Seven Fleet Capital Management LP acquired a new stake in shares of Century Therapeutics in the second quarter valued at about $10,652,174. Finally, Trails Edge Capital Partners LP purchased a new stake in Century Therapeutics during the second quarter worth about $10,130,674. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Stock Up 7.3%

Shares of IPSC opened at $1.47 on Tuesday. The stock has a 50 day moving average price of $1.83 and a 200 day moving average price of $2.10. The company has a market capitalization of $266.17 million, a price-to-earnings ratio of -1.58 and a beta of 1.67. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.06). On average, equities analysts anticipate that Century Therapeutics will post -0.51 EPS for the current fiscal year.

Century Therapeutics Company Profile

Century Therapeutics, Inc (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States.